Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

406 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples.
van Werkhoven E, Hinsley S, Frangou E, Holmes J, de Haan R, Hawkins M, Brown S, Love SB. van Werkhoven E, et al. Among authors: de haan r. BMC Med Res Methodol. 2020 Jun 22;20(1):162. doi: 10.1186/s12874-020-01012-z. BMC Med Res Methodol. 2020. PMID: 32571298 Free PMC article.
Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non-Small Cell Lung Cancer.
de Haan R, van den Heuvel MM, van Diessen J, Peulen HMU, van Werkhoven E, de Langen AJ, Lalezari F, Pluim D, Verwijs-Janssen M, Vens C, Schellens JHM, Steeghs N, Verheij M, van Triest B. de Haan R, et al. Among authors: de langen aj. Clin Cancer Res. 2021 Mar 1;27(5):1256-1266. doi: 10.1158/1078-0432.CCR-20-2551. Epub 2020 Dec 1. Clin Cancer Res. 2021. PMID: 33262140 Clinical Trial.
Phase I feasibility study of Olaparib in combination with loco-regional radiotherapy in head and neck squamous cell carcinoma.
Navran A, Al-Mamgani A, Elzinga H, Kessels R, Vens C, Tesselaar M, van den Brekel M, de Haan R, van Triest B, Verheij M. Navran A, et al. Among authors: de haan r. Clin Transl Radiat Oncol. 2023 Nov 4;44:100698. doi: 10.1016/j.ctro.2023.100698. eCollection 2024 Jan. Clin Transl Radiat Oncol. 2023. PMID: 38021094 Free PMC article.
Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells.
Verhagen CV, de Haan R, Hageman F, Oostendorp TP, Carli AL, O'Connor MJ, Jonkers J, Verheij M, van den Brekel MW, Vens C. Verhagen CV, et al. Among authors: de haan r. Radiother Oncol. 2015 Sep;116(3):358-65. doi: 10.1016/j.radonc.2015.03.028. Epub 2015 May 13. Radiother Oncol. 2015. PMID: 25981132
Occupational differences in a Dutch sample of patients with primary progressive aphasia, behavioral variant frontotemporal dementia, and Alzheimer's dementia.
Jiskoot LC, van den Berg E, Vollebergh H, de Haan R, de Boer L, Poos JM, Franzen S, van Hemmen J, Seelaar H. Jiskoot LC, et al. Among authors: de haan r. Appl Neuropsychol Adult. 2024 Apr 14:1-7. doi: 10.1080/23279095.2024.2339514. Online ahead of print. Appl Neuropsychol Adult. 2024. PMID: 38615690
406 results